See also Watson HG. RVO–Real value obscure. This issue, pp 1116–8; Le Gal G, Carrier M,
Kovacs MJ, Betancourt MT, Kahn SR, Wells PS, Anderson DA, Chagnon I, Solymoss S …

This study aimed to evaluate the cost-effectiveness of prophylaxis with rivaroxaban vs.
enoxaparin in the prevention of venous thromboembolism (VTE) after total hip replacement …

Rationale: Concomitant deep vein thrombosis (DVT) in patients with acute pulmonary
embolism (PE) has an uncertain prognostic significance. Objectives: In a cohort of patients …

Background The recanalization rate in patients with deep venous thrombosis (DVT) of the
legs treated with the direct oral anticoagulants (DOAC) is unknown. Methods In an Italian …

Venous thromboembolism (VTE) that includes deep vein thrombosis and/or pulmonary
embolism is a frequent, severe, and potentially lethal disease. After a first episode, VTE has …

Characterisation of heritable thrombophilic defects has facilitated an understanding of the
complex mechanisms influencing risk of venous thromboembolism. In parallel with this, the …

Whether to continue oral anticoagulant therapy indefinitely after completing 3 to 6months of
oral anticoagulant therapy for “unprovoked” venous thromboembolism (VTE), is one of the …

Dear Sir, Several clinical conditions and laboratory parameters have been evaluated as
predictors of recurrence after a first episode of venous thromboembolism (VTE). The risk of …

The risk of recurrent venous thromboembolism (VTE) approaches 40% in all patients after
10 years of follow-up. This risk is higher in patients with permanent risk factors for …

In contrast with the extensive and uniform documentation dealing with the short‐term
outcome of the deep vein thrombosis (DVT) of the lower extremities and of pulmonary …